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Apurinic/apyrimidinic (AP) endonuclease (APE) is a
multifunctional protein possessing both DNA repair and
redox regulatory activities. In base excision repair
(BER), APE is responsible for processing spontaneous,
chemical, or monofunctional DNA glycosylase-initiated
AP sites via its 5-endonuclease activity and 3-“end-
trimming” activity when processing residues produced
as a consequence of bifunctional DNA glycosylases. In
this study, we have fully characterized a mammalian
model of APE haploinsufficiency by using a mouse con-
taining a heterozygous gene-targeted deletion of the
APE gene (Apex/). Our data indicate that Apex/ mice
are indeed APE-haploinsufficient, as exhibited by a 40–
50% reduction (p < 0.05) in APE mRNA, protein, and
5-endonuclease activity in all tissues studied. Based on
gene dosage, we expected to see a concomitant reduc-
tion in BER activity; however, by using an in vitro G:U
mismatch BER assay, we observed tissue-specific alter-
ations in monofunctional glycosylase-initiated BER ac-
tivity, e.g. liver (35% decrease, p < 0.05), testes (55%
increase, p < 0.05), and brain (no significant difference).
The observed changes in BER activity correlated tightly
with changes in DNA polymerase  and AP site DNA
binding levels. We propose a mechanism of BER that
may be influenced by the redox regulatory activity of
APE, and we suggest that reduced APE may render a
cell/tissue more susceptible to dysregulation of the poly-
merase -dependent BER response to cellular stress.
Apurinic/apyrimidinic (AP)1 endonuclease (APE) is a multi-
functional protein involved in the maintenance of genomic in-
tegrity and in the regulation of gene expression. After the
initial discovery in Escherichia coli (1), APE was purified from
calf thymus DNA and extensively characterized as an endonu-
clease that cleaves the backbone of double-stranded DNA con-
taining AP sites (2, 3). APE homologues were subsequently
identified and characterized in many organisms, including
yeast as APN1 (4), mice as Apex (5, 6), and humans as HAP1
(7). In addition to its major 5-endonuclease activity, APE also
expresses minor 3-phosphodiesterase, 3-phosphatase, and
3 3 5-exonuclease activities (8), the biological significance of
which is controversial (9). Independent of its discovery as a
DNA repair protein, APE was also characterized as REF-1, for
redox factor-1, a redox activator of cellular transcription factors
(10–12). Although the molecular detail of APE redox activity is
still unclear (13), the discovery of APE as a regulator of tran-
scriptional activity may underscore the importance of its in-
volvement in cellular stress-response pathways.
APE is the primary enzyme responsible for recognition and
incision of non-coding AP sites in DNA arising as a conse-
quence of spontaneous, chemical, or DNA glycosylase-mediated
hydrolysis of the N-glycosyl bond initiated by the base excision
repair (BER) pathway. These lesions are particularly common,
arising at the rate of 50,000–200,000 AP sites per cell per day
under normal physiological conditions (14, 15). Unrepaired AP
sites may threaten genomic stability by serving as blocks to
DNA replication (16), by stalling RNA polymerase II during
transcription (17), or by promoting topoisomerase II-mediated
double strand breaks (18). Of the repair pathways available to
a cell (19, 20), BER is the main pathway responsible for repair-
ing AP sites in DNA. Initiation of BER is made possible by
recognition of a damaged base by either a monofunctional or
bifunctional DNA glycosylase, in addition to AP site recognition
by APE. In monofunctional glycosylase-initiated BER (MFG-
BER), a damaged or improper base is recognized and removed
by enzymatic hydrolysis of the N-glycosyl bond resulting in the
formation of an AP site. AP sites serve as a substrate for APE,
which incises the DNA backbone immediately 5 to the AP site
via its 5-endonuclease activity, producing a single strand
break with a normal 3-hydroxyl group and an abnormal 5-
deoxyribose 5-phosphate (dRP) residue (21). DNA polymerase 
(-pol) inserts a new base followed by the coupled -pol-medi-
ated excision of the abnormal 5-dRP, removal of which has
been shown to be rate-limiting (22). In bifunctional glycosylase-
initiated BER, the damaged base is recognized and removed by
a damage-specific DNA glycosylase followed by incision of the
DNA backbone by the associated AP lyase activity, yielding a
normal 5-terminal deoxynucleoside-5-phosphate residue and
an abnormal 3-terminal ,-unsaturated aldehyde residue
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that must be processed prior to repair completion (21). The
removal of the abnormal 3-blocking lesion by APE 3-phospho-
diesterase activity is believed to be rate-limiting (23); however,
this rate-limiting role is controversial (24–26). After APE rec-
ognition of AP sites, BER may proceed by one of two pathways:
(i) -pol-mediated single nucleotide insertion, similar to MFG-
BER, or (ii) 1 nucleotide strand-displacement synthesis, re-
quired to process modified (i.e. reduced, oxidized) AP sites and
involves components of the DNA replication machinery (27).
Completion of BER requires the nick sealing activity of DNA
ligase complexes (28).
A review of structural studies has proposed a model of BER
requiring highly intimate, yet transient protein-protein inter-
actions among BER enzymes to ensure proper damage repair,
with APE being at the center of activity (29). For example,
x-ray cross-complementing protein (XRCC1), a protein with no
known enzymatic activity, functions as both a scaffold protein
and modulator of BER via functional and physical interaction
with APE, bridging the incision and nick-sealing steps of BER
(30). APE has been shown also to interact with -pol, recruiting
it to the incised AP site and enhancing its rate-limiting dRPase
activity (31); this activity is also believed to be involved in the
repair of oxidative base lesions (32). The functional importance
of -pol in oxidative damage repair may be due to the interac-
tion of APE with bifunctional DNA glycosylases responsible for
recognizing and removing these lesions. For example, APE has
been shown to stimulate 8-oxoguanine DNA glycosylase
(OGG1) turnover and enhance its glycosylase activity while
minimizing its associated AP lyase activity (33, 34), with
XRCC1 accelerating this process (35), thus eliminating a po-
tentially rate-limiting step of APE and potentiating MFG-BER.
Similar results have also been obtained with other bifunctional
DNA glycosylases such as endonuclease III (hNTH1), respon-
sible for recognition and removal of ring-saturated pyrimidines
(36). These studies, in addition to a recent mathematical model
of BER throughput (37), suggest a preference for -pol-medi-
ated MFG-BER in vivo.
The objective of the research described in this study is to
characterize in more detail the phenotype of an APE heterozy-
gous knockout (Apex/) mouse reported previously (38), and to
address the effect of APE haploinsufficiency on BER capacity.
It is important to note that homozygous deletion of the APE
gene (Apex/) is embryonic lethal, but heterozygous mice sur-
vive and are fertile (38–40). Because the sequences encoding
both the DNA repair and redox regulatory activities of APE are
disrupted in Apex/ mice, it is unclear whether one or both of
these activities are necessary for embryogenesis. Although the
role of APE in the redox activation of p53 and other cellular
transcription factors suggests its importance in signal trans-
duction pathways, the embryonic lethality observed for APE
and three other BER genes (-pol, DNA ligase I, and XRCC1)
suggests a critical role for BER during embryogenesis (41).
Recent studies have implicated a role for p53 in the regulation
of the BER pathway (42); therefore, it is inviting to suggest that
APE repair activity in general, and perhaps APE redox regu-
latory activity in particular, is the reason for the embryonic
lethality observed when APE is deficient. Here we present
evidence that half the gene dosage of APE results in tissue-
specific alterations in MFG-BER and suggest that APE redox
activity, as opposed to repair per se, potentiates this phenotypic
effect. Data obtained from Apex/ mice may have relevant
transnational implications because APE variants have been
identified in the human population (43), and variants in DNA
repair have been associated with increased risk for disease
such as cancer (44, 45).
EXPERIMENTAL PROCEDURES
Animals
The experiments were performed on young (3–6 months) male
C57BL/6-specific pathogen-free mice in accordance with the National
Institutes of Health guidelines for the use and care of laboratory ani-
mals. The Wayne State University Animal Investigation Committee
approved the animal protocol. Mice were maintained on a 12-h light/
dark cycle and fed a standard lab diet and water ad libitum. The mice
were sacrificed by cervical dislocation, and the organs to be studied
were flash-frozen in liquid nitrogen and stored at 70 °C for later
enzyme studies and Western blot analyses. Tissues for total RNA iso-
lation and RT-PCR analysis were immediately homogenized in TRIzol®
Reagent (Invitrogen) according to the manufacturer’s protocol.
The APE heterozygous knockout (Apex/) mice were developed in
Friedberg’s laboratory as described previously (38). In order to obtain
the requisite number of animals for the study, the Apex/ mice were
inbred and maintained on a 12-h light/dark cycle and fed a standard lab
diet and water ad libitum. The mice appeared normal, were fertile, and
there was no retardation in food intake, weight gain, or growth rate;
however, it was observed that pups were not produced in expected
Mendelian ratios, with heterozygote births predominating, similar to
previous observations (39). A three-primer PCR strategy was employed
to genotype the animals generated by Apex/ intercrosses as described
previously (38).
mRNA Expression Analysis
The level of APE mRNA was measured using RT-PCR analysis using
AccessQuickTM RT-PCR System (Promega, Madison, WI) according to
the manufacturer’s protocol. Total cellular RNA was isolated from se-
lected tissues using TRIzol® Reagent (Invitrogen), and RNA concentra-
tion was determined by measuring UV absorption at 260/280 nm. Oli-
gonucleotide primers specific for the mouse Apex gene (forward, 5-CT-
CAAGATATGCTCCTGGAA-3; reverse, 5-GGTATTCCAGTCTTACC-
AGA-3) were designed using GeneFisher Interactive Primer Design
Tool (Bielefeld, Germany) and synthesized by Sigma-Genosys (The
Woodlands, TX). RT-PCR thermal cycling conditions were as follows:
48 °C for 45 min, 1 cycle; 95 °C for 2 min, 1 cycle; 95 °C for 1 min, 52 °C
for 1 min, 70 °C for 2 min, 22 cycles; and 70 °C for 5 min, 1 cycle. The
350-bp RT-PCR product was stained with ethidium bromide and ana-
lyzed on a 2% agarose gel. Intensity of the bands was detected and
quantified using a ChemiImagerTM system (AlphaInnotech, San Lean-
dro, CA) and expressed as the integrated density value (I.D.V) per g of
RNA used per reaction. Data were normalized based on the amount of
-actin present in each sample.
Isolation of Crude Nuclear Extract
Isolation of crude nuclear extract was accomplished using Sigma
CelLyticTM NuCLEARTM extraction kit (Sigma). All samples and tubes
were handled and chilled on ice, and all solutions were made fresh
according to the manufacturer’s protocol. Resultant nuclear extracts
were dialyzed against 1 liter of dialysis buffer (20 mM Tris-HCl, pH 8.0;
100 mM KCl; 10 mM NaS2O5; 0.1 mM DTT; 0.1 mM phenylmethylsulfonyl
fluoride; 1 g/ml pepstatin A) for 4–6 h at 4 °C using Slide-A-Lyzer®
minidialysis units (Pierce). Protein concentrations were determined
using Protein Assay Kit I (Bio-Rad).
Protein Expression Analysis
Western analysis was performed using 200 g of crude nuclear
extract isolated from selected tissues according to standard protocol.
Protein levels were determined using manufacturer recommended di-
lutions of monoclonal antisera developed against mouse APE/REF-1
(Novus Biologicals, Littleton, CO), and monoclonal antisera developed
against rat -pol (Ab-1 Clone 18S, NeoMarkers, Fremont, CA). The
bands were detected and quantified using a ChemiImagerTM system
(AlphaInnotech, San Leandro, CA) after incubation in SuperSignal®
West Pico Chemiluminescent Substrate (Pierce). Data are expressed as
the I.D.V. of the band per g of protein loaded.
APE Endonuclease Activity Assay
The 5-endonuclease activity of APE was analyzed using a quantita-
tive in vitro assay that measures the incision of a 26-mer duplex
oligonucleotide substrate containing a synthetic tetrahydrofuran (F) AP
site (upper strand, 5-AATTCACCGGTACCFTCTAGAATTCG-3; lower
strand, 5-CGAATTCTAGAGGGTACCGGTGAATT-3) as described
previously (46). Briefly, 2.5 pmol of radio-end-labeled and purified du-
plex AP DNA substrate was incubated with 100 ng of crude nuclear
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extract-selected tissues in a 10-l reaction mixture containing 50 mM
Hepes, pH 7.5; 50 mM KCl; 10 mM MgCl2; 2 mM DTT; 1 g/ml BSA; and
0.05% Triton X-100. The reaction mixtures were incubated for 15 min at
37 °C and stopped by the addition of 50 mM EDTA. Assay products (5 l)
were added to 15 l of loading dye (95% formamide, 5% glycerol, 10 mg
of xylene cyanol, 10 mg of bromphenol blue) and heated at 95 °C for 5
min. Aliquots (3 l) were run on a 15% denaturing 19:1 acrylamide/
bisacrylamide gel (SequaGel® Sequencing System, National Diagnos-
tics, Atlanta, GA) at 55 °C, soaked in fixing solution (10% glacial acetic
acid; 10% methanol), wrapped in Saran wrap, and exposed to a Molec-
ular Imaging Screen (Bio-Rad). Endonuclease activity (presence of a
14-mer band) was visualized and quantified using a Molecular Imager®
System (Bio-Rad) by calculating the relative amount of the 14-mer oligo
product with the unreacted 26-mer substrate (product/(product  sub-
strate)). Data are expressed as machine counts per ng of protein.
Base Excision Repair Assay
The principle of this assay is to measure MFG-BER activity. Radio
end-labeled and purified 30-bp oligonucleotides (upper strand, 5-ATA-
TACCGCGGUCGGCCGATCAAGCTTATTdd-3; lower strand, 3-ddT-
ATATGGCGCCGGCCGGCTAGTTCGAATAA-5) containing a G:U
mismatch and an HpaII restriction site (CCGG) were incubated in a
reaction mixture (100 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM DTT, 0.1
mM EDTA, 2 mM ATP, 0.5 mM NAD, 20 M dNTPs, 5 mM diTris-
phosphocreatine, 10 units of creatine phosphokinase) with 50 g of
crude nuclear extract isolated from selected tissues. The reaction mix-
tures were incubated for 30 min at 37 °C, followed by 5 min at 95 °C to
stop the reaction. The duplex oligonucleotides were allowed to reanneal
for 1 h at room temperature before being briefly centrifuged to pellet the
denatured proteins. Repair of the G:U mismatch to a correct G:C base
pair was determined via treatment of the duplex oligonucleotide with
20 units of HpaII (Promega, Madison, WI) for 1 h at 37 °C and analysis
by electrophoresis on a 20% denaturing 19:1 acrylamide/bisacrylamide
gel (SequaGel® Sequencing System, National Diagnostics, Atlanta,
GA). Repair activity (presence of a 16-mer band) was visualized and
quantified using a Molecular Imager® System (Bio-Rad) by calculating
the ratio of the 16-mer product with the 30-mer substrate (product/
substrate). Data are expressed as machine counts per g of protein.
Analysis of AP Site DNA Binding
The DNA binding ability of nuclear extracts isolated from selected
tissues was determined using electrophoretic mobility shift assays (EM-
SAs). Nuclear extracts (20 g) were incubated with 4 reaction buffer
(final concentrations: 50 mM Hepes, pH 8.0; 100 mM NaCl; 10 mM
EDTA; 1 mM DTT; 9.5% glycerol v/v) plus 1 g of BSA and 2 g of
poly(dI-dC) for 5 min at room temperature. A radio-end-labeled and
purified oligonucleotide probe containing an AP site (0.0125 pmol) was
added to the reaction mix and incubated for 30 min at room tempera-
ture. Negative controls (all components except nuclear extract) were
included in all experiments. In competitive assays, 100 molar excess
of unlabeled DNA was added to the reaction mixture. The protein-DNA
complex was resolved on a 5% non-denaturing polyacrylamide gel in
0.5 TBE buffer. Reaction products were visualized and quantified
using a Molecular Imager® System (Bio-Rad).
DNA Extraction
TEMPO Extraction of DNA—DNA for the aldehyde-reactive probe
slot blot (ASB) assay was extracted according to the method described
by Hofer and Moller (47) with some modifications. This method mini-
mizes artifactual DNA damage by using 20 mM TEMPO in all solutions
and reagents and by minimizing heat treatment of DNA. Briefly, tissue
was homogenized in ice-cold PBS and centrifuged (2000  g at 4 °C for
5 min). Resultant supernatant was decanted and pellet resuspended in
lysis buffer (Applied Biosystems, Foster City, CA). Proteinase K (30
units, Ambion, Austin, TX) was added, and samples were incubated
overnight at 4 °C, followed by phenol/chloroform and Sevag (chloroform/
isoamyl alcohol, 24:1) extraction. Extracted DNA was precipitated us-
ing 7.5% 4 M NaCl and 2 volumes of 100% cold ethanol and centrifuged
(2000  g at 4 °C for 5 min). Resultant pellet was washed in 70%
ethanol and resuspended in ice-cold PBS and rehydrated at 4 °C. The
samples were incubated with RNase A (2 g) and RNase T1 (1,000
units, Ambion, Austin, TX) for 30 min at 37 °C, and resultant DNA was
cold ethanol-precipitated, resuspended in deionized water at 4 °C, and
stored at 70 °C.
Gravity Tip Extraction of DNA—DNA for the random oligonucleotide
primed synthesis (ROPS) assay was isolated using Qiagen (Valencia,
CA) gravity tip columns as described in the manufacturer’s protocol.
This method generates large fragments of DNA (up to 150-kb) while
minimizing shearing.
DNA Damage Analysis
ASB—The ASB assay was carried out as described previously (14)
with slight modifications. TEMPO-extracted DNA (8 g) was incubated
in 30 l of PBS with 2 mM aldehyde-reactive probe (ARP) (Dojindo
Laboratories, Kumamoto, Japan) at 37 °C for 10 min. DNA was cold
ethanol-precipitated (as described above) and resuspended in 1 TE
buffer overnight at 4 °C. DNA was heat-denatured at 100 °C for 5 min,
quickly chilled on ice, and mixed with equal amount of 2 M ammonium
FIG. 1. Expression of the Apex gene in liver of Apex/ and Apex/ mice. A, the level of APE mRNA was measured using RT-PCR. The
350-bp cDNA product corresponding to the level of APE mRNA from each liver sample was detected and quantified using a ChemiImagerTM system
(AlphaInnotech, San Leandro, CA) and expressed as the I.D.V. of the band per g of RNA used per reaction. Data were normalized based on the
amount of -actin present in each sample. B, the level of the 37-kDa APE protein in 200 g of nuclear extract was determined by Western blot
analysis using monoclonal antisera developed against mouse APE. Data are expressed as the I.D.V. of the band per g of protein loaded. C, the
5-endonuclease activity of APE was analyzed using a 32P-end-labeled 26-mer duplex AP-DNA substrate (2.5 pmol) incubated with 100 ng of crude
nuclear extract from liver of Apex/ and Apex/ mice. Endonuclease activity (presence of a 14-bp fragment) was visualized and quantified using
a Molecular Imager® System by calculating the relative amount of the 14-bp product with the unreacted 26-bp substrate (product/(product 
substrate)). Data are expressed as machine counts per ng of protein. All values represent an average (S.E.) for data obtained from at least 5
animals in each group. *, value significantly different from Apex/ mice at p  0.05.
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acetate. DNA was immobilized on a nitrocellulose membrane
(Schleicher & Schuell) by using a Invitrogen Filtration Manifold sys-
tem. The membrane was washed in 5 SSC for 15 min at 37 °C and
then baked under vacuum at 80 °C for 30 min. The dried membrane was
incubated in a hybridization buffer (final concentrations: 20 mM Tris,
pH 7.5; 0.1 M NaCl; 1 mM EDTA; 0.5% casein w/v; 0.25% BSA w/v; 0.1%
Tween 20 v/v) for 30 min at room temperature. The membrane was then
incubated in the same hybridization buffer containing 100 l of strepta-
vidin-conjugated horseradish peroxidase (BioGenex, San Ramon, CA)
at room temperature for 45 min. Following incubation in horseradish
peroxidase, the membrane was washed three times for 5 min each at
37 °C in TBS, pH 7.5 (final concentrations: 0.26 M NaCl; 1 mM EDTA; 20
mM Tris, pH 7.5; 0.1% Tween 20). The membrane was incubated in ECL
(Pierce) for 5 min at room temperature and visualized using a Chemi-
ImagerTM system (AlphaInnotech, San Leandro, CA). Standards con-
taining known amounts of AP sites (14) were used to determine the
relative level of AP sites in liver DNA. Data are expressed as number of
AP sites per 106 nucleotides.
ROPS—The relative number of 3-OH group-containing DNA strand
breaks was quantified using a Klenow(exo) incorporation assay based
on the ability of Klenow to initiate DNA synthesis from 3-OH ends of
single strand DNA (48). Gravity tip extracted DNA (0.25 g) was
heat-denatured at 100 °C for 5 min and added to the Klenow reaction
buffer (0.5 mM dTTP, 0.5 mM dGTP, and 0.5 mM dATP; 0.33 M dCTP,
1 l of Klenow(exo)) with 10 Klenow buffer per manufacturer’s
protocol (New England Biolabs, Beverly, MA) and 5 Ci of [-32P]ATP
(3000 Ci/mmol, PerkinElmer Life Sciences). Reaction mixtures were
incubated at 16 °C for 30 min, and the reaction was stopped with the
addition of 25 l of 12.5 mM EDTA, pH 8.0. Samples (5 l) were spotted
onto scored and numbered Whatman DE81 paper and allowed to air
dry. The spotted chromatography paper was washed five times for 5
min in 0.5 M Na2HPO4 (dibasic) followed by a brief rinse in deionized
water two times and then allowed to air-dry. Paper was cut and placed
into scintillation vials with 2.5 ml of ScintiVerse mixture (Fisher).
Incorporation of [-32P]dCTP was quantified using a Packard scintilla-
tion counter.
Statistical Analysis
Statistical significance between means was determined using anal-
ysis of variance followed by the Fisher’s least significant difference test
where appropriate (49). A p value less than 0.05 was considered statis-
tically significant.
RESULTS
In order to elucidate the molecular effects of gene-targeted
disruption of the mouse APE gene (Apex), our laboratory has
characterized in detail a transgenic “knockout” mouse contain-
ing a heterozygous deletion of the APE gene (Apex/). As
reported previously, the Apex/ mice are embryonic lethal,
whereas the Apex/ animals are fertile, appear normal, and
exhibit reduced APE mRNA and APE protein levels in mouse
embryonic fibroblasts and brain cells as compared with their
Apex/ counterparts (38). In a series of experiments, we were
able to confirm whether APE heterozygosity would cause these
mice to exhibit haploinsufficiency with respect to APE in brain,
liver, and testes. In order to determine whether loss of a func-
tional allele of APE would result in reduced expression of this
gene, we have quantified the expression of APE via RT-PCR
analysis. By using total RNA isolated from liver, we observed a
40–50% decrease in APE mRNA (Fig. 1A) in Apex/ mice as
compared with their normal, wild-type (Apex/) counterparts.
Because differences in APE mRNA may not necessarily reflect
differences in APE protein levels, we also measured APE pro-
tein levels using Western blot analysis. We show a correspond-
ing 40–50% decrease in APE protein in liver (Fig. 1B). To
confirm that changes in APE expression (i.e. changes in mRNA
and protein levels) result in changes in APE enzymatic activity,
we measured APE 5-endonuclease activity using a 26-bp oli-
gonucleotide substrate containing a synthetic tetrahydrofuran
(F) AP site. As described previously (46), this in vitro 5-endo-
nuclease assay allows us to quantify APE enzymatic cleavage
of the 26-bp oligonucleotide substrate by analyzing the result-
ant 14-bp product on a denaturing sequencing gel. Data in Fig.
1C show that APE activity was reduced 40% in liver obtained
from Apex/ mice. Additionally, APE protein and activity were
also reduced 40–50% in testes and brain (Fig. 2, A and B).
Our data demonstrate that half the gene dosage for Apex
results in APE haploinsufficiency. Because APE is one of many
enzymes involved in the BER process, we were interested in
determining the effect of APE haploinsufficiency on BER ca-
pacity. We employed an enzymatic activity assay to measure
the ability of various tissues from Apex/ and Apex/ ani-
mals to repair a uracil-containing synthetic oligonucleotide. In
this assay, a double-stranded oligonucleotide containing a G:U
mismatch is incubated with crude nuclear extract isolated from
various tissues of Apex/ and Apex/ mice. If repair occurs,
FIG. 2. APE protein level and activity decrease in brain and
testes of Apex/ mice. The experiments were conducted using crude
nuclear extracts as described under “Experimental Procedures.” A, the
relative level of the 37-kDa APE protein in 200 g of nuclear extract
was determined by Western blot analysis using monoclonal antisera
developed against mouse APE. Data are expressed as the I.D.V. of the
band per g of protein loaded. Values represent an average (S.E.) for
data obtained from 5 animals in each group. *, value significantly
different from Apex/ mice at p  0.05. B, an autoradiograph of a
sequence gel indicating APE activity as visualized by the appearance of
a 14-bp fragment and expressed as machine counts per ng of protein.
Values represent an average (S.E.) for data obtained from at least 5
animals in each group. *, value significantly different from Apex/
mice at p  0.05.
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the G:U mismatch is converted into a correct G:C pair, creating
a HpaII restriction site. Thus, upon digestion with HpaII, re-
pair capacity can be quantified, i.e. the 12-bp band indicates
repair, and the 30-bp band indicates lack of repair. We find that
liver nuclear extracts isolated from Apex/ mice resulted in a
statistically significant decrease (35%, p  0.05) in BER activ-
ity as compared with the level of BER activity observed in liver
of Apex/ mice (Fig. 3A).
During BER processing, -pol removes the dRP residue after
AP endonuclease cleaves DNA at AP sites and inserts a new
nucleotide in the resulting gap. Because the dRPase activity of
-pol is the rate-determining step in BER (22), it is interesting
to know whether the diminished BER activity in liver tissue of
Apex/ mice is driven by down-regulation in -pol protein/
activity, i.e. to determine whether observed changes in BER
activity correlate to similar changes in -pol. We show corre-
sponding 50% decrease in -pol protein levels in the liver
extract of Apex/ mice (Fig. 3B), suggesting that the reduced
BER activity in liver of Apex/ mice is due to reduced -pol
level and/or activity.
It is of interest to determine whether reduced BER in the
liver of Apex/ mice is due to reduced APE endonuclease
activity. Thus, in an enrichment in vitro BER assay, we deter-
mined whether purified recombinant APE protein (Novus Bio-
logicals, Littleton, CO) would reverse the deficiency in BER
activity observed in the liver of Apex/ mice. Crude nuclear
extracts isolated from liver of Apex/ mice were enriched with
100 ng of human APE/REF-1 recombinant protein, and the
BER activity was quantified. The enrichment of the nuclear
extracts with the recombinant APE protein failed to restore
diminished BER activity in liver extract of Apex/ mice (Fig.
4A), whereas APE endonuclease activity was fully restored
FIG. 3. APE-haploinsufficient mice display tissue-specific BER capacity. The experiments were conducted using crude nuclear extracts
as described under “Experimental Procedures.” A, an autoradiograph of a sequence gel indicating repair activity as visualized by the appearance
of a 12-bp fragment. The relative level of base excision repair in selected tissues of mice was quantified using a Bio-Rad Molecular Imager® System,
and data were normalized based on the amount of protein used in each reaction. Data are expressed as machine counts per g of protein. Values
represent an average (S.E.) for data obtained from at least 5 animals in each group. M, 10-bp DNA ladder; , G:U mismatch oligonucleotide
incubated in the absence of nuclear extract and treated with HpaII restriction endonuclease; *, value significantly different from Apex/ mice at
p  0.05. B, the relative level of the 39-kDa -pol protein in 200 g of nuclear extract was determined by Western blot analysis using monoclonal
antisera developed against mouse -pol. The bands were detected and quantified using an AlphaInnotech ChemiImagerTM system. Data are
expressed as the I.D.V. of the band per g of protein loaded. Values represent an average (S.E.) for data obtained from at least 5 animals in each
group. *, value significantly different from Apex/ mice at p  0.05.
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(Fig. 4B). These data demonstrate that the down-regulation in
BER activity in liver of Apex/ mice is not due to reduced APE
endonuclease activity in the extract.
In order to determine directly whether APE-haploinsuffi-
cient mice display altered levels of DNA damage, we have
measured the presence of AP sites and single strand breaks in
isolated liver DNA from Apex/ mice as compared with liver
DNA from Apex/ mice. By using a highly sensitive quantita-
tive assay that measures the number of aldehydic DNA lesions
corresponding to AP sites, we observed no significant difference
in the level of AP sites in Apex/ mice as compared with
Apex/ mice (Fig. 5A). Similarly, by using the ROPS assay to
measure the number of single strand breaks in liver DNA, we
observed no significant difference in single strand breaks in
Apex/ as compared with Apex/ (Fig. 5B); thus, the lack of
accumulation of DNA damage in Apex/ mice suggest that
APE haploinsufficiency in liver does not cause an accumulation
of genotoxic DNA repair intermediate products in young mice.
We have demonstrated that BER activity is reduced in liver
of Apex/ mice, and that this reduction does not appear to be
due to loss of APE endonuclease activity. In addition to the
characterization of APE haploinsufficiency on BER in liver, we
wanted to investigate whether other tissues exhibited a similar
effect. We initially compared the relative level of APE protein
in selected tissues of wild type (Apex/), and we show that in
testes the APE protein level was severalfold higher than in
both liver and brain (Fig. 6). We chose to analyze brain and
testes because these two tissues are highly susceptible to the
deleterious consequences of high levels of oxidative damage,
which is recognized and repaired by BER. Based on gene dos-
age, we expected to see a concomitant reduction in BER activity
in nuclear extracts isolated from both brain and testes of
Apex/ mice as compared with nuclear extracts obtained from
Apex/ mice. However, the data presented in Fig. 3A depicts
tissue-specific alterations in BER activity. By using the mono-
functional glycosylase-initiated BER assay (i.e. G:U mismatch
repair), nuclear extracts isolated from the brain of Apex/
mice did not show any significant difference in repair activity
as compared with nuclear extracts isolated from the brain of
Apex/ mice, although a downward trend was observed. How-
ever, when measuring BER activity in testes, Apex/ mice
exhibited a significant increase (55%, p  0.05) in BER. Ac-
cordingly, observed changes in BER correlated to similar
changes in -pol, i.e. using Western blot analysis we observe a
38% decrease (p  0.05) in brain and a 23% increase (p  0.05)
in testes of Apex/ mice as compared with Apex/ mice
(Fig. 3B).
The BER pathway is initiated by the recognition and binding
of BER proteins to damaged DNA, e.g. altered bases and/or AP
sites, forming a repair complex. Therefore, it is of interest to
determine whether Apex/ mice display any reduced activity
in the recognition of DNA lesions, specifically binding to an AP
site in vitro. By using EMSAs, we quantified the ability of
nuclear extracts obtained from brain, liver, and testes to bind
to a radio-end-labeled oligonucleotide containing an AP site. As
shown in Fig. 7, the nuclear extracts isolated from Apex/
mice exhibit tissue-specific binding to AP sites in a manner
corresponding to the alterations in BER activity observed
above. In other words, a significant reduction in AP site bind-
ing activity was observed in both liver and brain tissue, where
BER/-pol was shown to be reduced, whereas AP site binding
activity was induced in testes, where BER/-pol is up-regu-
lated. Thus, these data indicate that loss of APE may affect
BER activity by altering the formation of a BER repair complex
on DNA containing AP lesions.
DISCUSSION
In this study, we have characterized the effect of APE hap-
loinsufficiency on mammalian BER using mice containing a
heterozygous gene-targeted deletion of APE (Apex/). We re-
port data demonstrating that decreased gene-dosage of APE
results in tissue-specific differences in the ability of cells/tis-
sues to carry out MFG-BER in vitro. Specifically, BER was
shown to decrease in liver and increase in testes, whereas a
FIG. 4. Enrichment with recombi-
nant APE protein does not affect
BER activity in liver of Apex/ mice.
The experiments were conducted using
crude nuclear extracts and extracts en-
riched with 100 ng of recombinant APE
protein as described under “Experimental
Procedures.” A, the relative level of BER
activity in liver tissue of Apex/ mice
was visualized and quantified using a
Bio-Rad Molecular Imager® System, and
data were normalized based on the
amount of protein used in each reaction.
The BER data are expressed as machine
counts per g of protein. B, APE activity
was visualized and quantified using a
Bio-Rad Molecular Imager® System by
calculating the relative amounts of the
14-bp product with the unreacted 26-bp
substrate (product/(product  substrate)).
The APE data are expressed as machine
counts per ng of protein. , negative
control.
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decreased trend in brain was observed. Studies characterizing
the effect of reduced APE have shown increased sensitivity to
oxidative stress in cells (50, 51) and in mice (38), supporting our
recent observation that BER is responsible for the repair of
oxidative stress (52). Similarly, explanted homozygous Apex/
blastocysts displayed increased sensitivity to ionizing radiation
(39), whereas neuronal cells from Apex/ mice were sensitive
to menadione (38). However, it is currently unclear whether
enhanced sensitivity to stress is strictly due to loss of APE
endonuclease activity, loss of APE redox regulatory activity, or
both.
The tissue-specific differences in BER observed in response
to APE haploinsufficiency may be due to differences in the
relative level of BER. For example, we have shown previously
(53) that testes have the highest relative level of MFG-BER as
compared with liver and brain. Additionally, Intano et al. (54)
have also shown that MFG-BER is highest in mixed germ cells,
followed by liver, and then brain. With respect to the relative
tissue levels of APE, its importance for cellular survivability
suggests that its expression in cells would be ubiquitous. How-
ever, Tan et al. (55) have shown that although APE mRNA was
ubiquitously expressed in rats, the levels varied significantly
among tissues with the highest level observed in testes and
comparably low levels in both liver and brain. Although tissue-
specific differences in the level of mRNA do not necessarily
imply tissue-specific protein levels, we have shown that al-
though APE protein was detectable in all tissues studied, testes
displayed a significantly higher level than both liver and brain.
Furthermore, tissue-specific variations in cellular and subcel-
lular localization of APE have been observed in humans, with
spermatocytes and hepatocytes showing unusually high levels
of cytoplasmic staining in addition to expected nuclear local-
ization (56, 57).
A question that remains is why a 40–50% reduction in the
expression and endonuclease activity of APE would cause BER
to respond differently among various tissue types. It has been
clearly demonstrated and widely accepted that -pol is the
rate-limiting enzyme in MFG-BER (22). Our laboratory has
also demonstrated that -pol expression and activity strongly
correlate with MFG-BER under a variety of environmental
stimuli (52, 53, 58, 59). A recent study (37) examining kinetic
data of various BER enzymes has also suggested that -pol-
mediated MFG-BER may be the predominant BER pathway in
vivo. As such, the finding that decreased levels of APE in livers
of APE-haploinsufficient mice resulted in decreased MFG-BER
was surprising. However, the current dogma of BER requires
that BER proteins function in a highly coordinated series of
complex protein-protein and protein-DNA interactions to min-
imize the formation of toxic DNA repair intermediates. For
example, APE has been shown to interact with -pol, facilitat-
ing its loading onto AP DNA, and stimulates its rate-determin-
ing dRP excision activity (31). Here we present data demon-
strating that reduced APE results in decreased AP site DNA
binding activity, which may consequently affect BER activity
by altering the formation of a repair complex on AP lesions.
FIG. 5. Analysis of AP sites and single strand breaks in liver
DNA of Apex/ and Apex/ mice. A, liver DNA was isolated using
the TEMPO extraction method, and the number of AP sites was meas-
ured using the ASB assay as described under “Experimental Proce-
dures.” Data are expressed as the I.D.V. of the band per g of DNA
loaded. Values represent an average (S.E.) for data obtained from at
least 5 animals in each group. ADL, aldehydic DNA lesions, which
correspond to the level of AP sites. B, liver DNA was isolated using
gravity tip extraction columns, and the number of single strand breaks
was measured using the ROPS assay as described under “Experimental
Procedures.” Data are expressed as machine counts per min corre-
sponding to the level of [-32P]dCTP incorporation as quantified by a
Packard scintillation counter. Values represent an average (S.E.) for
data obtained from at least 5 animals in each group.
FIG. 6. Relative levels of APE protein in various tissues of
Apex/ mice. Crude nuclear extracts were isolated from brain, liver,
and testes using Sigma CelLyticTM NuCLEARTM extraction kit as de-
scribed under “Experimental Procedures.” The relative level of APE
protein in 200 g of nuclear extract was determined by Western blot
analysis. The bands were detected and quantified using an Alpha-
Innotech ChemiImagerTM system. Data are expressed as the I.D.V. of
the band per g of protein loaded. Values represent an average (S.E.)
for data obtained from at least 5 animals in each group.
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Furthermore, stabilization of -pol to AP DNA complexes by
p53 has been shown to require the presence of APE (60). Al-
though the evidence suggests that a decrease in BER in liver of
APE-haploinsufficient mice may be due to decreased protein-
DNA stabilization when APE is deficient, in testes a similar
decrease in APE protein levels resulted in an increase in AP
DNA binding activity as well as an increase in BER. Thus, the
ability of a BER repair complex to bind to AP sites and initiate
BER activity appears to be regulated by -pol and not APE.
Because BER declined in liver in response to APE haploin-
sufficiency, we expected that enrichment of the BER reaction
mixtures with recombinant APE would fully restore BER ac-
tivity. However, APE enrichment did not replenish BER activ-
ity, whereas APE endonuclease activity was fully restored.
This finding provides convincing evidence that the mechanism
behind the decline in BER in response to APE haploinsuffi-
ciency is not due to a decrease in APE endonuclease activity
and provides further support that -pol is indeed rate-deter-
mining, i.e. BER activity is tightly correlated with -pol protein
level/activity. Further support for the role of -pol, and not
APE, in determining BER capacity is shown by data demon-
strating a corresponding up-regulation of -pol and BER in
testes of Apex/ mice, where APE is haploinsufficient.
When examining DNA damage in liver, decreased BER did
not result in increased single strand breaks or AP sites, sug-
gesting that in the absence of stress, liver of Apex/ mice may
still possess the capacity to protect against DNA damage re-
paired by BER. This finding is in support of our recent study
that BER deficiency due to -pol haploinsufficiency does not
significantly increase DNA damage in young mice, whereas
environmental stress and/or age promoted higher levels of
DNA strand breaks (52, 58). In line with these studies, we
suggest that environmental stress could potentially exacerbate
an APE-haploinsufficient phenotype by rendering Apex/ tis-
sues susceptible to DNA damage. This notion is supported by
Meira et al. (38), reporting that neuronal cells from Apex/
mice were sensitive to menadione. In addition, preliminary
data from our laboratory suggest that whereas basal levels of
NF-B activation are not altered in response to APE haploin-
sufficiency, Apex/ mice exposed to 2-nitropropane-induced
oxidative stress were unable to stimulate activation of NF-B
as efficiently as wild-type mice (data not shown).
In testes, we demonstrate that APE haploinsufficiency up-
regulates BER activity, with corresponding increases in the
level of -pol protein and the level of binding to AP site DNA.
The tissue-specific stimulation of damage recognition and BER
activity in testes incurred by the loss of APE in Apex/ mice
may be the result of increased susceptibility to the background
levels of stress that are present within the cellular milieu of
rapidly dividing cells. Paradoxically, a delicate balance be-
tween oxidant production and oxidant removal must be present
in testes, because reactive oxygen species have been shown to
play an important role in normal fertilization (61). We have
established previously that oxidative stress is capable of induc-
ing the -pol-mediated BER pathway in various tissues (52).
Furthermore, in response to an active state of spermatogenesis,
there is a constant level of oxidative stress in testes (62, 63),
and unrepaired oxidative damage has been shown to induce
abnormal sperm with reduced fertility (64). However, recent
reports (65) have indicated that nuclear DNA of human sper-
matozoa is relatively resistant to damage induced by H2O2 and
iron treatment in vitro. This particular paradox may be due to
the high relative level of BER found in testes (53, 54, 66) and
the ability of APE to function both as a BER enzyme and as a
redox regulatory molecule. Because BER may function inde-
pendently of APE (67), it is likely that under circumstances of
FIG. 7. APE-haploinsufficient mice display tissue-specific differences in binding to DNA containing AP sites. The experiments were
conducted using crude nuclear extracts and radio-end-labeled oligonucleotide containing a synthetic tetrahydrofuran AP site as described under
“Experimental Procedures.” The relative level of AP site DNA binding in various tissues of Apex/ and Apex/ mice were determined using
EMSA. The level of bandshift was determined using a Bio-Rad Molecular Imager® System, and data were normalized based on the amount of
protein used in each reaction. Data are expressed as machine counts per g of protein. Values represent an average (S.E.) for data obtained from
at least 5 animals in each group. Comp., nuclear extracts incubated in the presence of 100 molar excess of unlabeled AP site DNA to confirm
binding specificity; n.s., nonspecific binding; *, value significantly different from Apex/ mice at p  0.05.
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constant stress due to high levels of reactive oxygen species,
APE may be partitioned to function as a redox protein to
stimulate transcription factors involved in various cellular
stress-response pathways. Nonetheless, these data provide fur-
ther evidence that APE endonuclease activity is not rate-deter-
mining in MFG-BER and strongly suggest that the involve-
ment of APE as a signaling molecule in the BER response to
DNA damage may help maintain oxidative homeostasis in
testes.
Based on the data presented herein, it is inviting to suggest
that tissue-specific differences in BER capacity observed in
APE-haploinsufficient cells/tissues is not due to a simple alter-
ation in APE endonuclease activity but perhaps is due to an
alteration in the redox function of APE, as well as to differences
in the susceptibility of specific tissues to background levels of
stress. We propose that a decrease in APE redox activation of
p53 may be the mechanism by which BER displays tissue-
specific activity. Data in the literature support this premise by
showing the following: p53 is involved in the cellular response
to stress (68); p53 activation is APE-dependent (69, 70); and
p53 may regulate BER activity, perhaps through alteration in
the expression of -pol (42, 60). Because APE is known to
promote the activation of p53 in a redox-dependent and -inde-
pendent manner (69, 71), it is likely that the decrease in BER
observed in liver of Apex/ mice may be due to a decrease in
the activation of p53. In support, down-regulation of APE by
antisense RNA has been shown to reduce dramatically p53
activation (70), and preliminary data show a reduction in acti-
vation of p53 in liver of Apex/ mice (data not shown). Thus,
reduced APE redox activity may render a cell/tissue more sus-
ceptible to environmental stress by altering cellular responses
such as BER. As such, APE appears to form a unique link
between BER and the cellular signaling mechanisms responsi-
ble for the DNA damage response.
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